Inventor · disambiguated record
Marco Gottardis
Also filed as: FEDER JOHN N · GOTTARDIS MARCO · GOTTARDIS MARCO M
22 granted patents·12 pending applications·364 citations·filing 2000–2023
96Inventor score
Files withBRISTOL MYERS SQUIBB CO14JANSSEN PHARMACEUTICA NV7CAMPHAUSEN RAY2JANSSEN BIOTECH INC2HUANG FEI1
Top patents by PatentIndex Score
34 records- 0196US9771411B2Method of treating cancer by administering EGFR and EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 26, 2017·22 cites·20 claims
- 0296US9017655B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Apr 28, 2015·36 cites·10 claims
- 0396US8343501B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Jan 1, 2013·45 cites·19 claims
- 0496US8221765B2Multivalent fibronectin based scaffold domain proteinsCAMPHAUSEN RAY·Filed 2009·Granted Jul 17, 2012·66 cites·20 claims
- 0595US9902762B2Multivalent fibronectin based scaffold domain proteinsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Feb 27, 2018·28 cites·10 claims
- 0695US8728483B2Multivalent fibronectin based scaffold domain proteinsCAMPHAUSEN RAY·Filed 2012·Granted May 20, 2014·38 cites·29 claims
- 0795US6960474B2Method for the treatment of a condition remediable by administration of a selective androgen receptor modulatorBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 1, 2005·82 cites·8 claims
- 0892US10774130B2Method of treating cancer by administering multivalent fibronectin based scaffold domain proteinsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Sep 15, 2020·6 cites·15 claims
- 0991US10183987B2Polynucleotides encoding bispecific EGFR/IGF-IR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 22, 2019·7 cites·13 claims
- 1090US11207311B2Method of treating prostate cancerJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Dec 28, 2021·6 cites·23 claims
- 1190US10954286B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 23, 2021·2 cites·20 claims
- 1286US11986470B2Methods of treating prostate cancerJANSSEN PHARMACEUTICA NV·Filed 2023·Granted May 21, 2024·0 cites·22 claims
- 1383US11992486B2Methods of treating prostate cancerJANSSEN PHARMACEUTICA NV·Filed 2022·Granted May 28, 2024·0 cites·12 claims
- 1483US11986468B2Methods of treating prostate cancerJANSSEN PHARMACEUTICA NV·Filed 2022·Granted May 21, 2024·0 cites·22 claims
- 1583US11986469B2Methods of treating prostate cancerJANSSEN PHARMACEUTICA NV·Filed 2022·Granted May 21, 2024·0 cites·22 claims
- 1681US7655688B2Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Feb 2, 2010·5 cites·8 claims
- 1779US12383543B2Methods of treating prostate cancerJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Aug 12, 2025·0 cites·19 claims
- 1878US8492328B2Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulatorsHUANG FEI·Filed 2008·Granted Jul 23, 2013·4 cites·7 claims
- 1977US6624154B1Compositions and methods for treatment of hyperproliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 23, 2003·13 cites·39 claims
- 2075US7199227B2Polynucleotides encoding human histone deacetylase HDAC9cBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Apr 3, 2007·3 cites·14 claims
- 2170US2021017252A1Multivalent fibronectin based scaffold domain proteinsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2262US2018028521A1Methods of Treating Prostate CancerJANSSEN PHARMACEUTICA NV·Filed 2017·Application pending·0 cites
- 2358US7138246B2Methods for identifying or screening for agents that modulate 17β-HSD3BRISTOL MYERS SQUIBB CO·Filed 2005·Granted Nov 21, 2006·1 cites·3 claims
- 2454US11793843B2Prostate neoantigens and their usesJANSSEN BIOTECH INC·Filed 2020·Granted Oct 24, 2023·0 cites·29 claims
- 2553US2021315986A1Psma and steap1 vaccines and their usesJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2653US2005075358A1Methods for treating IGF1R-inhibitor induced hyperglycemiaFiled 2004·Application pending·0 cites
- 2752US2004106605A1Synergistic methods and compositions for treating cancerFiled 2003·Application pending·0 cites
- 2852US2004072760A1Synergistic methods and compositions for treating cancerFiled 2003·Application pending·0 cites
- 2949US2004209930A1Synergistic methods and compositions for treating cancerFiled 2004·Application pending·0 cites
- 3048US2004122080A1Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancerFiled 2002·Application pending·0 cites
- 3148US2005256048A1Selective androgen receptor modulators and methods for their identification, design and useSALVATI MARK E·Filed 2005·Application pending·0 cites
- 3246US2004087548A1Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor functionFiled 2002·Application pending·0 cites
- 3341US2004068762A1Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elementsFiled 2003·Application pending·0 cites
- 3438US2011123545A1Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marco Gottardis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →